RANDOMIZED VACCINE TRIAL OF SINGLE-DOSE OF KILLED LEISHMANIA-MAJOR PLUS BCG AGAINST ANTHROPONOTIC CUTANEOUS LEISHMANIASIS IN BAM, IRAN

Citation
I. Sharifi et al., RANDOMIZED VACCINE TRIAL OF SINGLE-DOSE OF KILLED LEISHMANIA-MAJOR PLUS BCG AGAINST ANTHROPONOTIC CUTANEOUS LEISHMANIASIS IN BAM, IRAN, Lancet, 351(9115), 1998, pp. 1540-1543
Citations number
19
Categorie Soggetti
Medicine, General & Internal
Journal title
LancetACNP
ISSN journal
01406736
Volume
351
Issue
9115
Year of publication
1998
Pages
1540 - 1543
Database
ISI
SICI code
0140-6736(1998)351:9115<1540:RVTOSO>2.0.ZU;2-D
Abstract
Background A vaccine consisting of a single dose of whole-cell autocla ve-killed Leishmania major (ALM) mixed with BCG was assessed in compar ison with BCG alone against anthroponotic (human to human transmission ) cutaneous leishmaniasis in a randomised double-blind trial in Bam, I ran. Methods 3637 schoolchildren, aged 6-15 years, with no history of cutaneous leishmaniasis and no response to a leishmanin skin test, wer e randomly assigned to receive 1 mg ALM mixed with BCG (n=1839), or BC G alone (n=1798). Safety of the vaccine and the incidence of confirmed -cases of cutaneous leishmaniasis were followed up for 2 years. Findin gs Side-effects were those usually associated with BCG vaccination, bu t-tended to persist longer in the ALM+BCG group. After exclusion of fo ur cases occurring within 80 days of vaccination tone in the ALM+BCG g roup and three in the BCG group), the 2-year incidence of cutaneous le ishmaniasis did not differ significantly between vaccine and BCG group s: 2-8% vs 3-3%, respectively (total cases 112). A sex-stratified anal ysis showed that in boys the vaccine conferred a protective efficacy o f 18% and 78% for the first and second years, respectively-a crude 2-y ear overall protection of 55% (95% CI 19-75%, p<0.01). In the first 9 months after vaccination, there was a non-significant excess of cases in the ALM+BCG group (25 vs 16), whereas the incidence of cutaneous le ishmaniasis-thereafter was significantly reduced in the ALM+BCG group (27 vs 44, p<0.05). Interpretation A single dose of ALM+BCG was safe a nd more immunogenic than BCG alone, as measured by leishmanin shin tes t. The exact reason-for the apparent protective effect of the vaccine in boys is unknown, and maybe a chance finding. However, since boys ar e more exposed to the infection, which is indicated-by higher disease prevalence in boys in this study population, the preferential protecti ve effect in boys may have resulted from a greater booster effect prod uced by repeated exposure to infected sandflies. Booster injections or alternative adjuvants should be tried to improve the potential effica cy of this vaccine.